Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO89-100 in Severe Hypertriglyceridemia (Phase 2, randomized, double-blind, placebo-controlled)
2020-000641-13Phase 2Completed
- Sponsor
- 89bio
- Start
- Jul 2020
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertriglyceridemia comparing BIO89-100 with Placebo (2 arms). Primary endpoint: Primary: Percentage change in serum triglycerides from baseline to Week 8. Started Jul 2020; status: completed.
02
Drugs
pegozafermin
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on 2020-000641-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000641-13.